Evidence map›Paper›PMID 41488531›Full record

ReviewRSC advances2025

MXenes in diabetes: diagnostic and therapeutic applications.

Meisam Samadzadeh, Mahshid Danesh, Atefeh Zarepour, Arezoo Khosravi, Ali Zarrabi, Siavash Iravani

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Meisam SamadzadehDepartment of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istinye University Istanbul 34396 Türkiye.
Mahshid DaneshDepartment of Bioinformatics, Biocenter, University of Würzburg Am Hubland 97074 Würzburg Germany.
Atefeh ZarepourDepartment of Biology, Faculty of Arts and Sciences, Kocaeli University 41001 İzmit Kocaeli Türkiye.
Arezoo KhosraviDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University Istanbul 34959 Türkiye.
Ali ZarrabiDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University Istanbul 34396 Türkiye alizarrabi@gmail.com.ORCID https://orcid.org/0000-0003-0391-1769
Siavash IravaniIndependent Researcher W Nazar ST, Boostan Ave Isfahan Iran siavashira@gmail.com.ORCID https://orcid.org/0000-0003-3985-7928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review highlights the promising role of MXenes and their composites in diabetes management, emphasizing their dual utility in diagnostics and therapeutics. MXenes' exceptional electrical conductivity, hydrophilicity, mechanical robustness, and tunable surface chemistry facilitate the design of sensitive and selective biosensors for real-time and non-invasive monitoring of key diabetes biomarkers like glucose and acetone. Therapeutically, MXene-based materials enhance healing of diabetic complications such as foot ulcers by modulating inflammation, scavenging reactive oxygen species, promoting angiogenesis, and supporting tissue regeneration

Identifiers

PMID41488531
PMCPMC12757849

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.